Option Care Health (NASDAQ:OPCH) Rating Increased to Hold at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Option Care Health (NASDAQ:OPCH) to a hold rating in a research note issued to investors on Monday,Zacks.com reports.

Several other equities analysts also recently commented on OPCH. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $26.00 price objective on shares of Option Care Health in a research report on Friday, May 1st. JPMorgan Chase & Co. lowered their price objective on Option Care Health from $40.00 to $33.00 and set an “overweight” rating on the stock in a research report on Monday, May 4th. UBS Group lowered their price objective on Option Care Health from $45.00 to $39.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Truist Financial set a $30.00 price objective on Option Care Health in a research report on Friday, May 1st. Finally, Stephens set a $30.00 target price on Option Care Health in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $30.54.

Option Care Health Price Performance

NASDAQ OPCH opened at $20.08 on Monday. The company has a market capitalization of $3.15 billion, a PE ratio of 15.57, a price-to-earnings-growth ratio of 1.14 and a beta of 0.67. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.07 and a current ratio of 1.64. The business’s fifty day moving average is $24.17 and its 200 day moving average is $29.48. Option Care Health has a fifty-two week low of $18.01 and a fifty-two week high of $36.80.

Option Care Health (NASDAQ:OPCH) last released its earnings results on Thursday, April 30th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.03. Option Care Health had a return on equity of 18.17% and a net margin of 3.64%.The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.39 billion. During the same period in the previous year, the business earned $0.40 earnings per share. Option Care Health’s quarterly revenue was up 1.3% compared to the same quarter last year. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. Sell-side analysts predict that Option Care Health will post 1.64 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Harry M. Jansen Kraemer, Jr. bought 36,610 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were bought at an average cost of $21.41 per share, for a total transaction of $783,820.10. Following the completion of the transaction, the director owned 450,000 shares of the company’s stock, valued at approximately $9,634,500. This represents a 8.86% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Timothy P. Sullivan bought 24,154 shares of Option Care Health stock in a transaction dated Thursday, May 7th. The stock was purchased at an average cost of $20.69 per share, for a total transaction of $499,746.26. Following the purchase, the director owned 73,383 shares of the company’s stock, valued at approximately $1,518,294.27. This trade represents a 49.06% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 73,264 shares of company stock worth $1,548,316. Corporate insiders own 1.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Durable Capital Partners LP grew its stake in shares of Option Care Health by 134.2% during the second quarter. Durable Capital Partners LP now owns 8,237,577 shares of the company’s stock valued at $267,557,000 after buying an additional 4,720,988 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in shares of Option Care Health by 12.1% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,958,800 shares of the company’s stock valued at $221,707,000 after buying an additional 752,058 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Option Care Health by 6.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 4,248,425 shares of the company’s stock valued at $135,355,000 after buying an additional 247,118 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Option Care Health by 0.9% during the first quarter. Dimensional Fund Advisors LP now owns 3,876,856 shares of the company’s stock valued at $104,368,000 after buying an additional 36,208 shares during the last quarter. Finally, Southpoint Capital Advisors LP grew its stake in shares of Option Care Health by 20.0% during the first quarter. Southpoint Capital Advisors LP now owns 3,600,000 shares of the company’s stock valued at $96,912,000 after buying an additional 600,000 shares during the last quarter. Institutional investors own 98.05% of the company’s stock.

About Option Care Health

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.